Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pravastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 10/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.84 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.84 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pravastatin SCHEMBL2817795 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL899410 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL14472019 | 0.98 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL3013 | 0.98 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL5598406 | 0.98 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL3014 | 0.98 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL27522597 | 0.98 | HMGCR (1.00) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL6317379 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL2225672 | 0.98 | HMGCR (0.97) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 | |
| Pravastatin SCHEMBL2175991 | 0.97 | HMGCR (0.98) | HMGCRALOX15SLCO1B1SLC22A8SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108675931-A | A kind of low barium statin calcium and preparation method thereof | 合肥合源药业有限公司 | 2018-10-19 | — | — | CN | claimed |
| EP-3035933-A2 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | Resverlogix Corporation (CA) | 2016-06-29 | — | — | EP | claimed |
| CN-104739855-A | Statin-related drug composition as well as capsule preparation and preparation method thereof | Zhaoke pharmaceutical guangzhou co ltd | 2015-07-01 | — | — | CN | claimed |
| WO-2015025228-A2 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | RESVERLOGIX CORP. (CA) | 2015-02-26 | — | — | WO | claimed |
| US-20140142127-A1 | Stable Compositions of HMG-COA Reductase Inhibitors and Omega-3 Oils | ALMBURG, LLC (US) | 2014-05-22 | — | — | US | claimed |
| WO-2012140490-A2 | PROCESS FOR PREPARING QUINOLINE DERIVATIVE | AUROBINDO PHARMA LIMITED (IN) | 2012-10-18 | — | — | WO | claimed |
| WO-2012025939-A1 | PITAVASTATIN CALCIUM AND PROCESS FOR ITS PREPARATION | CADILA HEALTHCARE LIMITED (IN) | 2012-03-01 | — | — | WO | claimed |
| US-20110294841-A1 | NOVEL STATIN PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF TREATMENT | GUZMAN HECTOR (US) | 2011-12-01 | — | — | US | claimed |
| EP-2387561-A2 | IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE (3R,5S)-7-Ý2-CYCLOPROPYL-4-(4-FLUOROPHENYL) QUINOLIN-3-YL¨-3,5-DIHYDROXY-6(E)-HEPTENOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN Laboratories Limited (IN) | 2011-11-23 | — | — | EP | claimed |
| WO-2010089770-A2 | IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE (3R,5S)-7-[2-CYCLOPROPYL-4-(4-FLUOROPHENYL) QUINOLIN-3-YL]-3,5-DIHYDROXY-6(E)-HEPTENOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN LABORATORIES LIMITED (IN) | 2010-08-12 | — | — | WO | claimed |
| US-7772277-B2 | Formulations comprising fenofibrate and a statin, and related methods of treatment | TRANSFORM PHARMACEUTICALS, INC. (US) | 2010-08-10 | — | — | US | claimed |
| US-7642287-B2 | storage stable drug contains pravastatin calcium and an omega-3 oil, wherein the omega-3 oil comprises 46% ethyl ester of eicosapentaenoic acid, 38% ethyl ester of docosahexaenoic acid; anticholesterol agent, antilipemic agent; treating atherosclerosis, hyperlipidemia, cardiovascular disease | TRANSFORM PHARMACEUTICALS, INC. (US) | 2010-01-05 | — | — | US | claimed |
| EP-2086945-A2 | NOVEL PROCESS FOR THE PREPARATION OF STATINS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Satyanarayana Reddy, Manne (IN) | 2009-08-12 | — | — | EP | claimed |
| CN-101500555-A | Novel formulations comprising fenofibrate and a statin and related methods of treatment | TRANSFORM PHARMACEUTICALS INC (US) | 2009-08-05 | — | — | CN | claimed |
| WO-2008044243-A9 | NOVEL PROCESS FOR THE PREPARATION OF STATINS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SATYANARAYANA REDDY MANNE (IN) | 2008-11-13 | — | — | WO | claimed |
| EP-1922065-A2 | NOVEL FORMULATIONS COMPRISING FENOFIBRATE AND A STATIN, AND RELATED METHODS OF TREATMENT | Transform Pharmaceuticals, Inc. (US) | 2008-05-21 | — | — | EP | claimed |
| WO-2008044243-A2 | NOVEL PROCESS FOR THE PREPARATION OF STATINS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SATYANARAYANA REDDY MANNE (IN) | 2008-04-17 | — | — | WO | claimed |
| WO-2007019373-A2 | NOVEL FORMULATIONS COMPRISING FENOFIBRATE AND A STATIN, AND RELATED METHODS OF TREATMENT | TRANSFORM PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| US-20070032546-A1 | NOVEL FORMULATIONS COMPRISING FENOFIBRATE AND A STATIN, AND RELATED METHODS OF TREATMENT | ALMBURG, LLC | 2007-02-08 | — | — | US | claimed |
| US-20240189221-A1 | METHODS AND FORMULATIONS FOR TREATING VASCULAR DISEASE | ENDOPERFUSION SOLUTIONS, LLC | 2024-06-13 | — | — | US | disclosed |
| CN-116942850-B | Nanometer drug delivery system for vulnerable plaque | 北京茵诺医药科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-116942850-A | Nanometer drug delivery system for vulnerable plaque | 北京茵诺医药科技有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-3386503-B1 | KITS FOR TREATING VASCULAR DISEASE | ENDOPERFUSION SOLUTIONS LLC (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-111249248-B | Blood lipid reducing medicine and preparation method thereof | 北京阳光诺和药物研究股份有限公司 | 2021-03-05 | — | — | CN | disclosed |
| EP-3630125-A2 | SENOLYTIC COMPOUNDS | United Kingdom Research and Innovation (GB) | 2020-04-08 | — | — | EP | disclosed |
| US-20180360742-A1 | METHODS AND FORMULATIONS FOR TREATING VASCULAR DISEASE | ENDOPERFUSION SOLUTIONS, LLC | 2018-12-20 | — | — | US | disclosed |
| WO-2018215795-A2 | SENOLYTIC COMPOUNDS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2018-11-29 | — | — | WO | disclosed |
| CN-108675931-A | A kind of low barium statin calcium and preparation method thereof | 合肥合源药业有限公司 | 2018-10-19 | — | — | CN | disclosed |
| EP-3386503-A1 | METHODS AND FORMULATIONS FOR TREATING VASCULAR DISEASE | Endoperfusion Solutions, LLC (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017100767-A1 | METHODS AND FORMULATIONS FOR TREATING VASCULAR DISEASE | ENDOPERFUSION SOLUTIONS, LLC (US) | 2017-06-15 | — | — | WO | disclosed |
| EP-3131578-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | Novartis AG (CH) | 2017-02-22 | — | — | EP | disclosed |
| EP-3054940-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | Mochida Pharmaceutical Co., Ltd. (JP) | 2016-08-17 | — | — | EP | disclosed |
| EP-3035933-A2 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | Resverlogix Corporation (CA) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015158927-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | NOVARTIS AG (CH) | 2015-10-22 | — | — | WO | disclosed |
| CN-104739855-A | Statin-related drug composition as well as capsule preparation and preparation method thereof | Zhaoke pharmaceutical guangzhou co ltd | 2015-07-01 | — | — | CN | disclosed |
| WO-2015053379-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015025228-A2 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | RESVERLOGIX CORP. (CA) | 2015-02-26 | — | — | WO | disclosed |
| WO-2014195965-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITOR INTERMEDIATES | MYLAN LABORATORIES LTD (IN) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014108795-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF CHIRAL DIOL SULFONES AND STATINS | AUROBINDO PHARMA LIMITED (IN) | 2014-07-17 | — | — | WO | disclosed |
| US-20140142127-A1 | Stable Compositions of HMG-COA Reductase Inhibitors and Omega-3 Oils | ALMBURG, LLC (US) | 2014-05-22 | — | — | US | disclosed |
| CN-103784417-A | Pravastatin calcium tablet containing magnesium silicate and preparation method thereof | CHONGQING RUEPEAK PHARMACEUTICAL CO LTD | 2014-05-14 | — | — | CN | disclosed |
| CN-103784417-A | Pravastatin calcium tablet containing magnesium silicate and preparation method thereof | CHONGQING RUEPEAK PHARMACEUTICAL CO LTD | 2014-05-14 | — | — | CN | disclosed |
| CN-103690955-A | Ticagrelor-containing drug composition as well as preparation method and application thereof | FUZHOU QIANZHENG PHARMACEUTICAL CO LTD | 2014-04-02 | — | — | CN | disclosed |
| WO-2013098773-A1 | CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM | DR. REDDY'S LABORATORIES LIMITED (IN) | 2013-07-04 | — | — | WO | disclosed |
| CN-102885797-A | Composition containing pravastatin calcium as well as preparation method and application thereof | FUZHOU NEPTUNUS FUYAO PHARMACEUTICAL CO LTD | 2013-01-23 | — | — | CN | disclosed |
| CN-102885797-A | Composition containing pravastatin calcium as well as preparation method and application thereof | FUZHOU NEPTUNUS FUYAO PHARMACEUTICAL CO LTD | 2013-01-23 | — | — | CN | disclosed |
| WO-2012106584-A2 | PITAVASTATIN SALTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-08-09 | — | — | WO | disclosed |
| US-8232295-B2 | Treating vascular events with statins by inhibiting PAR-1 and PAR-4 | HEARTDRUG RESEARCH, L.L.C. (US) | 2012-07-31 | — | — | US | disclosed |
| WO-2010146348-A9 | CRYSTALLINE FORM OF PEMIROLAST | CARDOZ AB (SE) | 2012-05-03 | — | — | WO | disclosed |
| EP-2443120-A2 | NEW CRYSTALLINE FORM OF PEMIROLAST | Cardoz AB (SE) | 2012-04-25 | — | — | EP | disclosed |
| WO-2012025939-A1 | PITAVASTATIN CALCIUM AND PROCESS FOR ITS PREPARATION | CADILA HEALTHCARE LIMITED (IN) | 2012-03-01 | — | — | WO | disclosed |
| US-20110294841-A1 | NOVEL STATIN PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF TREATMENT | GUZMAN HECTOR (US) | 2011-12-01 | — | — | US | disclosed |
| EP-2387561-A2 | IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE (3R,5S)-7-Ý2-CYCLOPROPYL-4-(4-FLUOROPHENYL) QUINOLIN-3-YL¨-3,5-DIHYDROXY-6(E)-HEPTENOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN Laboratories Limited (IN) | 2011-11-23 | — | — | EP | disclosed |
| US-20110160236-A1 | Treating Vascular Events with Statins by Inhibiting PAR-1 and PAR-4 | HEARTDRUG RESEARCH, L.L.C. | 2011-06-30 | — | — | US | disclosed |
| WO-2010146348-A2 | NEW CRYSTALLINE FORM OF PEMIROLAST | CARDOZ AB (SE) | 2010-12-23 | — | — | WO | disclosed |
| US-7842716-B2 | Treating vascular events with statins by inhibiting PAR-1 and PAR-4 | HeartDrug Research, LLC (US) | 2010-11-30 | — | — | US | disclosed |
| WO-2010089770-A2 | IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE (3R,5S)-7-[2-CYCLOPROPYL-4-(4-FLUOROPHENYL) QUINOLIN-3-YL]-3,5-DIHYDROXY-6(E)-HEPTENOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN LABORATORIES LIMITED (IN) | 2010-08-12 | — | — | WO | disclosed |
| US-7772277-B2 | Formulations comprising fenofibrate and a statin, and related methods of treatment | TRANSFORM PHARMACEUTICALS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| WO-2010077062-A2 | PREPARATION METHOD OF STATIN COMPOUND AND BENZOTHIAZOLYL SULFONE COMPOUND USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2010-07-08 | — | — | WO | disclosed |
| US-7642287-B2 | storage stable drug contains pravastatin calcium and an omega-3 oil, wherein the omega-3 oil comprises 46% ethyl ester of eicosapentaenoic acid, 38% ethyl ester of docosahexaenoic acid; anticholesterol agent, antilipemic agent; treating atherosclerosis, hyperlipidemia, cardiovascular disease | TRANSFORM PHARMACEUTICALS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-2120919-A1 | NEW COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | Cardoz AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| EP-2104534-A1 | NEW COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | Cardoz AB (SE) | 2009-09-30 | — | — | EP | disclosed |
| EP-2086945-A2 | NOVEL PROCESS FOR THE PREPARATION OF STATINS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Satyanarayana Reddy, Manne (IN) | 2009-08-12 | — | — | EP | disclosed |
| US-20090182008-A1 | CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| CN-100506796-C | Method for preparing high optical purity pitavastatin calcium raw material drug | SHANGHAI YAOMING KANGDE NEW ME (CN) | 2009-07-01 | — | — | CN | disclosed |
| EP-2024341-A2 | NOVEL PROCESS FOR STATINS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Satynarayana Reddy, Manne (IN) | 2009-02-18 | — | — | EP | disclosed |
| US-20090042979-A1 | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment | TRANSFORM PHARMACEUTICALS INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008044243-A9 | NOVEL PROCESS FOR THE PREPARATION OF STATINS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SATYANARAYANA REDDY MANNE (IN) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008087371-A1 | NEW COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | CARDOZ AB (SE) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008074975-A1 | NEW COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | CARDOZ AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008044243-A2 | NOVEL PROCESS FOR THE PREPARATION OF STATINS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SATYANARAYANA REDDY MANNE (IN) | 2008-04-17 | — | — | WO | disclosed |
| EP-1786414-A4 | NOVEL STATIN PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF TREATMENT | TRANSFORM PHARMACEUTICALS INC (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007132482-A2 | NOVEL PROCESS FOR THE PREPARATION OF PITAVASTATIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | SATYANARAYANA REDDY MANNE (IN) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007130714-A1 | NOVEL STATIN PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF TREATMENT | TRANSFORM PHARMACEUTICALS, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007125547-A2 | NOVEL PROCESS FOR STATINS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SATYANARAYANA REDDY MANNE (IN) | 2007-11-08 | — | — | WO | disclosed |
| CN-1993121-A | Novel statin pharmaceutical compositions and related methods of treatment | TRANSFORM PHARMACEUTICALS INC (US) | 2007-07-04 | — | — | CN | disclosed |
| EP-1786414-A2 | NOVEL STATIN PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF TREATMENT | Transform Pharmaceuticals, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1755607-A2 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | Pharmix Corporation (US) | 2007-02-28 | — | — | EP | disclosed |
| CN-1876633-A | Method for preparing high optical purity pitavastatin calcium raw material drug | SHANGHAI YAOMING KANGDE NEW ME (CN) | 2006-12-13 | — | — | CN | disclosed |
| WO-2006058943-A1 | METHOD OF OBTAINING PURIFIED PRAVASTATIN SODIUM | ERCROS INDUSTRIAL, S.A. (ES) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006028524-A2 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | PHARMIX CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060034815-A1 | Novel statin pharmaceutical compositions and related methods of treatment | ALMBURG, LLC | 2006-02-16 | — | — | US | disclosed |
| WO-2006017698-A2 | NOVEL STATIN PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF TREATMENT | TRANSFORM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20050215618-A1 | Treating vascular events with statins by inhibiting PAR-1 and PAR-4 | HEARTDRUG RESEARCH, L.L.C. | 2005-09-29 | — | — | US | disclosed |
| US-20050215618-A1 | Treating vascular events with statins by inhibiting PAR-1 and PAR-4 | HEARTDRUG RESEARCH, L.L.C. | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189221-A1 | METHODS AND FORMULATIONS FOR TREATING VASCULAR DISEASE | LIPG, APOB, LIPA | HMGCR 5/4885ALOX15 255/4885SLCO1B1 1066/4885 |
| US-20090182008-A1 | CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM | CTSC, CACYBP, CA4 | HMGCR 345/4885ALOX15 4690/4885SLCO1B1 239/4885 |
| US-20180360742-A1 | METHODS AND FORMULATIONS FOR TREATING VASCULAR DISEASE | LIPG, APOB, LIPA | HMGCR 5/4885ALOX15 255/4885SLCO1B1 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.